Swiss ministers have met with senior executives of pharmaceutical companies Roche and Novartis to discuss the outlook for the ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

European shares were broadly flat on Monday, as investors refrained from making big bets ahead of a key U.S. inflation data, ...

And if you're looking for top dividend-paying companies to put your money in right now, let's consider two excellent ...

The overwhelming federal nature of this subject is apparent,” the lawsuit alleges. “States are not free to tinker with ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.

A New Jersey pharmaceutical company filed a lawsuit in federal court last week challenging a new Maine law aimed to protect a ...

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital ...